86 results on '"Cornelis L. Harteveld"'
Search Results
2. Adapting the ACMG/AMP variant classification framework
- Author
-
Cornelis L. Harteveld, Bin Alwi Zilfalil, Celeste Bento, Carsten W. Lederer, Joanne Traeger-Synodinos, Marina Kleanthous, Coralea Stephanou, Petros Kountouris, Landry E. Nfonsam, Eirini Fylaktou, Tamara T. Koopmann, Kyriaki Michailidou, Hashim Halim-Fikri, and John S. Waye
- Subjects
medicine.medical_specialty ,ClinGen VCEP ,Genomics ,Computational biology ,Interpretation Process ,Biology ,symbols.namesake ,Genetics ,medicine ,Humans ,hemoglobinopathy ,Genetic Testing ,Pathology, Molecular ,variant classification ,Genetics (clinical) ,Globin genes ,Genome, Human ,Genetic Variation ,ACMG/AMP criteria ,globin gene variants ,Guideline ,medicine.disease ,United States ,Hemoglobinopathies ,Hemoglobinopathy ,Mendelian inheritance ,symbols ,Medical genetics - Abstract
Accurate and consistent interpretation of sequence variants is integral to the delivery of safe and reliable diagnostic genetic services. To standardize the interpretation process, in 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published a joint guideline based on a set of shared standards for the classification of variants in Mendelian diseases. The generality of these standards and their subjective interpretation between laboratories has prompted efforts to reduce discordance of variant classifications, with a focus on the expert specification of the ACMG/AMP guidelines for individual genes or diseases. Herein, we describe our experience as a ClinGen Variant Curation Expert Panel to adapt the ACMG/AMP criteria for the classification of variants in three globin genes (HBB, HBA2, and HBA1) related to recessively inherited hemoglobinopathies, including five evidence categories, as use cases demonstrating the process of specification and the underlying rationale.
- Published
- 2021
3. Recommendations for diagnosis and treatment of methemoglobinemia
- Author
-
Wilma Barcellini, Noémi B. A. Roy, Roberta Russo, Antonis Kattamis, Paola Bianchi, Cornelis L. Harteveld, Stefano Ghirardello, Immacolata Andolfo, Razan Mohty, EuroBloodNet, Mariane de Montalembert, Andreas E. Kulozik, Elisa Fermo, Patrick G. Gallagher, Josef T. Prchal, Davis Rees, Achille Iolascon, Richard van Wijk, Lucia De Franceschi, Gergely Toldi, Antonella Gambale, Gian Luca Forni, Ali T. Taher, Iolascon, A., Bianchi, P., Andolfo, I., Russo, R., Barcellini, W., Fermo, E., Toldi, G., Ghirardello, S., Rees, D., Van Wijk, R., Kattamis, A., Gallagher, P. G., Roy, N., Taher, A., Mohty, R., Kulozik, A., De Franceschi, L., Gambale, A., De Montalembert, M., Forni, G. L., Harteveld, C. L., and Prchal, J.
- Subjects
Pediatrics ,medicine.medical_specialty ,Globin genes ,Consensus ,business.industry ,CYB5R3 ,Disease Management ,Consensu ,Hematology ,Disease ,Methemoglobinemia ,medicine.disease ,Methemoglobin ,Diagnosis, Differential ,Therapeutic approach ,Adulthood - period ,hemic and lymphatic diseases ,medicine ,Humans ,Hemoglobin ,business ,Human - Abstract
Methemoglobinemia is a rare disorder associated with oxidization of divalent ferro-iron of hemoglobin (Hb) to ferri-iron of methemoglobin (MetHb). Methemoglobinemia can result from either inherited or acquired processes. Acquired forms are the most common, mainly due to the exposure to substances that cause oxidation of the Hb both directly or indirectly. Inherited forms are due either to autosomal recessive variants in the CYB5R3 gene or to autosomal dominant variants in the globin genes, collectively known as HbM disease. Our recommendations are based on a systematic literature search. A series of questions regarding the key signs and symptoms, the methods for diagnosis, the clinical management in neonatal/childhood/adulthood period, and the therapeutic approach of methemoglobinemia were formulated and the relative recommendations were produced. An agreement was obtained using a Delphi-like approach and the experts panel reached a final consensus >75% of agreement for all the questions.
- Published
- 2021
4. The evolving role of next-generation sequencing in screening and diagnosis of hemoglobinopathies
- Author
-
Ahlem Achour, Tamara T. Koopmann, Frank Baas, and Cornelis L. Harteveld
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Physiology ,Thalassemia ,Mini Review ,alpha-thalassemia ,Alpha-thalassemia ,Computational biology ,Monogenic disease ,DNA sequencing ,beta-thalassemia ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Physiology (medical) ,Medicine ,QP1-981 ,business.industry ,Beta thalassemia ,medicine.disease ,hemoglobinopathy diagnostics ,030104 developmental biology ,030220 oncology & carcinogenesis ,NGS ,β-thalassemia ,Mendelian inheritance ,symbols ,Medical genetics ,α-thalassemia ,WES ,sickle cell disease ,business ,Research setting ,WGS - Abstract
During the last few years, next-generation sequencing (NGS) has undergone a rapid transition from a research setting to a clinical application, becoming the method of choice in many clinical genetics laboratories for the detection of disease-causing variants in a variety of genetic diseases involving multiple genes. The hemoglobinopathies are the most frequently found Mendelian inherited monogenic disease worldwide and are composed of a complex group of disorders frequently involving the inheritance of more than one abnormal gene. This review aims to present the role of NGS in both screening and pre- and post-natal diagnostics of the hemoglobinopathies, and the added value of NGS is discussed based on the results described in the literature. Overall, NGS has an added value in large-scale high throughput carrier screening and in the complex cases for which common molecular techniques have some inadequacies. It is proven that the majority of thalassemia cases and Hb variants can be diagnosed using routine analysis involving a combined approach of hematology, hemoglobin separation, and classical DNA methods; however, we conclude that NGS can be a useful addition to the existing methods in the diagnosis of these disorders.
- Published
- 2021
5. Usefulness of NGS for Diagnosis of Dominant Beta-Thalassemia and Unstable Hemoglobinopathies in Five Clinical Cases
- Author
-
Valeria Rizzuto, Tamara T. Koopmann, Adoración Blanco-Álvarez, Barbara Tazón-Vega, Amira Idrizovic, Cristina Díaz de Heredia, Rafael Del Orbe, Miriam Vara Pampliega, Pablo Velasco, David Beneitez, Gijs W. E. Santen, Quinten Waisfisz, Mariet Elting, Frans J. W. Smiers, Anne J. de Pagter, Jean-Louis H. Kerkhoffs, Cornelis L. Harteveld, Maria del Mar Mañú-Pereira, Institut Català de la Salut, [Rizzuto V] Recerca translacional en càncer en la infància i l’adolescència– Rare Anemia Disorders Research Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. Josep Carreras Leukaemia Research Institute, Badalona, Spain. Department of Medicine, Universitat de Barcelona, Barcelona, Spain. [Koopmann TT] Department of Clinical Genetics, Leiden University Medical Center, ERN-EuroBloodNet Member, Leiden, Netherlands. [Blanco-Álvarez A, Tazón-Vega B] Hematologic Molecular Genetics Unit, Hematology Department, Hospital Universitari Vall d’Hebron, ERN-EuroBloodNet Member, Barcelona, Spain. [Idrizovic A, Mañú-Pereira MDM] Recerca translacional en càncer en la infància i l’adolescència– Rare Anemia Disorders Research Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. [Díaz de Heredia C, Velasco P] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. [Beneitez D] Unitat de Trastorns dels glòbuls vermells, Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Human genetics, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Pediatrics ,medicine.medical_specialty ,Blood transfusion ,técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Anemia ,Physiology ,medicine.medical_treatment ,Dominant beta-thalassemia ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hemolítica::anemia hemolítica congénita::talasemia::talasemia beta [ENFERMEDADES] ,lcsh:Physiology ,whole exome sequencing ,03 medical and health sciences ,0302 clinical medicine ,Targeted ngs ,Seqüències d'inserció de l'ADN ,Physiology (medical) ,medicine ,unstable hemoglobinopathies ,Exome sequencing ,030304 developmental biology ,Original Research ,next generation sequencing ,0303 health sciences ,Hb Debrousse ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::hemoglobinopatías [ENFERMEDADES] ,lcsh:QP1-981 ,business.industry ,Hemoglobinopatia ,medicine.disease ,Hemolysis ,Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis, DNA [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,3. Good health ,Hemic and Lymphatic Diseases::Hematologic Diseases::Hemoglobinopathies [DISEASES] ,Chronic hemolytic anemia ,Talassèmia ,030220 oncology & carcinogenesis ,dominant beta-thalassemia ,business ,rare anemia disorders ,Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hemolytic::Anemia, Hemolytic, Congenital::Thalassemia::beta-Thalassemia [DISEASES] - Abstract
Seqüenciació de nova generació; Trastorns d’anèmia rars; Hemoglobinopaties inestables Next generation sequencing; Rare anemia disorders; Unstable hemoglobinopathies Secuenciación de nueva generación; Trastornos raros de la anemia; Hemoglobinopatías inestables Unstable hemoglobinopathies (UHs) are rare anemia disorders (RADs) characterized by abnormal hemoglobin (Hb) variants with decreased stability. UHs are therefore easily precipitating, causing hemolysis and, in some cases, leading to dominant beta-thalassemia (dBTHAL). The clinical picture of UHs is highly heterogeneous, inheritance pattern is dominant, instead of recessive as in more prevalent major Hb syndromes, and may occur de novo. Most cases of UHs are not detected by conventional testing, therefore diagnosis requires a high index of suspicion of the treating physician. Here, we highlight the importance of next generation sequencing (NGS) methodologies for the diagnosis of patients with dBTHAL and other less severe UH variants. We present five unrelated clinical cases referred with chronic hemolytic anemia, three of them with severe blood transfusion dependent anemia. Targeted NGS analysis was performed in three cases while whole exome sequencing (WES) analysis was performed in two cases. Five different UH variants were identified correlating with patients’ clinical manifestations. Four variants were related to the beta-globin gene (Hb Bristol—Alesha, Hb Debrousse, Hb Zunyi, and the novel Hb Mokum) meanwhile one case was caused by a mutation in the alpha-globin gene leading to Hb Evans. Inclusion of alpha and beta-globin genes in routine NGS approaches for RADs has to be considered to improve diagnosis’ efficiency of RAD due to UHs. Reducing misdiagnoses and underdiagnoses of UH variants, especially of the severe forms leading to dBTHAL would also facilitate the early start of intensive or curative treatments for these patients. This study was supported by funding from the authors’ institutions and the European Commission H2020-MSCA-ITN-2019, Grant Agreement N860436, “EVIDENCE.”
- Published
- 2021
6. Cyanosis, hemolysis, decreased HbA1c and abnormal co-oximetry in a patient with hemoglobin M Saskatoon [HBB:c.190C > T p.His64Tyr]
- Author
-
Eva-Leonne Göttgens, Adriaan J. van Gammeren, Kristian Baks, Cornelis L. Harteveld, and Kristel Goossens
- Subjects
Erythrocyte Indices ,medicine.medical_specialty ,Reticulocytosis ,Anemia ,Hemoglobins, Abnormal ,DNA Mutational Analysis ,Methemoglobinemia ,Methemoglobin ,Hb variant ,Internal medicine ,medicine ,Humans ,hemoglobinopathy ,Genetic Predisposition to Disease ,Oximetry ,Mean corpuscular volume ,methemoglobin ,Alleles ,Genetic Association Studies ,Glycated Hemoglobin ,medicine.diagnostic_test ,business.industry ,cyanosis ,Hematology ,co-oximetry ,hemoglobin ,medicine.disease ,anemia ,Hemolysis ,Phenotype ,Hemoglobinopathy ,Endocrinology ,Amino Acid Substitution ,Female ,Hemoglobin ,medicine.symptom ,business ,Biomarkers ,Hb M Saskatoon - Abstract
We describe a first Dutch case of Hb M Saskatoon (HBB:c.190C > T p.His64Tyr) in a 47-year-old female Dutch patient who presented with cyanosis, hemolysis, and abnormal co-oximetry. A mean corpuscular volume (MCV) of 105 fL caused by reticulocytosis (160 x 10(9)/L) and low red blood cell count (3.6 x 10(12)/L) suggested an increased erythrocyte turnover. An HPLC glyco-globin analysis revealed a decreased HbA1c fraction of 12.3 mmol/mmol, HbA0 of 93.3% and an additional unidentified fraction at 1.2 min. DNA sequencing revealed a missense mutation in the HBB gene, (HBB:c.190C > T p.His64Tyr), known as Hb M Saskatoon, a variant which has been previously identified as an unstable hemoglobin variant leading to methemoglobinemia and anemia. In this report, we describe the clinical and remarkable laboratory aspects of our patient with Hb M Saskatoon, and the consequences for treatment and drug use.
- Published
- 2021
7. A new gene associated with a β-thalassemia phenotype: the observation of variants in SUPT5H
- Author
-
Cornelis L. Harteveld, Joanne Traeger-Synodinos, Jennichjen Slomp, Christina Vrettou, Sharda Bisoen, Maaike Verschuren, Nicolette S. den Hollander, Jeanet A.C. ter Huurne, Ahlem Achour, Gijs W. E. Santen, Frédéric Galactéros, Claudia A. L. Ruivenkamp, Rianne Schaap, Rob Castel, Tamara T. Koopmann, Serge Pissard, Sandra G.J. Arkesteijn, Anneliese Grimbergen, Jeroen Knijnenburg, Frank Baas, Linda Vijfhuizen, Human Genetics, and ARD - Amsterdam Reproduction and Development
- Subjects
Genetics ,Male ,business.industry ,Thalassemia ,Immunology ,beta-Thalassemia ,MEDLINE ,Genetic Variation ,Nuclear Proteins ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Biochemistry ,Phenotype ,Text mining ,medicine ,Humans ,Female ,Genetic Predisposition to Disease ,Transcriptional Elongation Factors ,business ,Gene ,Biomarkers ,Genetic Association Studies - Published
- 2020
8. An Unusual Compound Heterozygosity for Hb O-Arab (HBB: c.364G>A) and Hb D-Los Angeles (HBB: c.364G>C)
- Author
-
Cornelis L. Harteveld, Leonie Pelkmans, Roseri J A C Roelofsen-de Beer, Adriaan J van Gammeren, and Corné C W van Endschot
- Subjects
Proband ,Microcytic anemia ,Biochemistry (medical) ,Clinical Biochemistry ,Blood count ,Hematology ,Biology ,medicine.disease ,Compound heterozygosity ,Molecular biology ,03 medical and health sciences ,0302 clinical medicine ,newborn ,030220 oncology & carcinogenesis ,medicine ,Hb D-Los Angeles ,Hb O-Arab ,Hemoglobin ,Hb D Los Angeles ,Genetics (clinical) ,030215 immunology - Abstract
We report a newborn with a compound heterozygosity for Hb O-Arab (HBB: 364G>A) and Hb D-Los Angeles (HBB: 364G>C). To the best of our knowledge, the combination of these two hemoglobin (Hb) variants has not been identified and reported before. The variants of the proband and parents were identified by high-performance liquid chromatography (HPLC) and capillary electrophoresis (CE). DNA analysis was performed to confirm the variants. The levels of Hb variants of the proband were determined post-partum, at 3 months and 1 year after birth. Blood count analysis after 1 year revealed that the proband had a mild microcytic anemia. Furthermore, HPLC and CE analysis revealed an equal distribution of Hb D-Los Angeles compared to Hb O-Arab at the age of 1 year. The follow-up of the patient, suggested that the Hb combination is clinically silent or mild.
- Published
- 2020
9. Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia
- Author
-
Achille Iolascon, Immacolata Andolfo, Roberta Russo, Wilma Barcellini, Elisa Fermo, Gergely Toldi, Stefano Ghirardello, Davis Rees, Richard Van Wijk, Antonis Kattamis, Patrick G. Gallagher, Noemi Roy, Ali Taher, Razan Mohty, Andreas Kulozik, Lucia De Franceschi, Antonella Gambale, Mariane De Montalembert, Gian Luca Forni, Cornelis L. Harteveld, Josef Prchal, Paola Bianchi, on behalf of SWG of Red Cell and Iron of EHA and EuroBloodNet, Iolascon, Achille, Andolfo, Immacolata, Russo, Roberta, Barcellini, Wilma, Fermo, Elisa, Toldi, Gergely, Ghirardello, Stefano, Rees, Davi, Van Wijk, Richard, Kattamis, Antoni, Gallagher, Patrick G, Roy, Noemi, Taher, Ali, Mohty, Razan, Kulozik, Andrea, De Franceschi, Lucia, Gambale, Antonella, De Montalembert, Mariane, Forni, Gian Luca, Harteveld, Cornelis L, Prchal, Josef, and Bianchi, Paola
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,MEDLINE ,Methemoglobinemia ,medicine.disease ,Editorial ,Internal medicine ,Medicine ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,business - Published
- 2021
10. ATR16 Syndrome: Mechanisms Linking Monosomy to Phenotype
- Author
-
Joanne Traeger-Synodinos, Christian Babbs, Amanda Dixon-McIver, Shiwangini Kumar, Joanne Slater, Veronica J. Buckle, Marjolein Kriek, Sharon W. Horsley, Paul Ooijevaar, Douglas R. Higgs, Cornelis L. Harteveld, Jill M. Brown, and Evie Maifoshie
- Subjects
Genetics ,0303 health sciences ,Monosomy ,Genetic counseling ,030305 genetics & heredity ,Biology ,medicine.disease ,Phenotype ,03 medical and health sciences ,chemistry.chemical_compound ,Chromosome 16 ,chemistry ,medicine ,Copy-number variation ,Allele ,Gene ,DNA ,030304 developmental biology - Abstract
BackgroundSporadic deletions removing 100s-1000s kb of DNA, and variable numbers of poorly characterised genes, are often found in patients with a wide range of developmental abnormalities. In such cases, understanding the contribution of the deletion to an individual’s clinical phenotype is challenging.MethodsHere, as an example of this common phenomenon, we analysed 34 patients with simple deletions of ∼177 to ∼2000 kb affecting one allele of the well characterised, gene dense, distal region of chromosome 16 (16p13.3), referred to as ATR-16 syndrome. We characterised precise deletion extent and screened for genetic background effects, telomere position effect and compensatory up regulation of hemizygous genes.ResultsWe find the risk of developmental and neurological abnormalities arises from much smaller terminal chromosome 16 deletions (∼400 kb) than previously reported. Beyond this, the severity of ATR-16 syndrome increases with deletion size, but there is no evidence that critical regions determine the developmental abnormalities associated with this disorder. Surprisingly, we find no evidence of telomere position effect or compensatory upregulation of hemizygous genes, however, genetic background effects substantially modify phenotypic abnormalities.ConclusionsUsing ATR-16 as a general model of disorders caused by sporadic copy number variations, we show the degree to which individuals with contiguous gene syndromes are affected is not simply related to the number of genes deleted but also depends on their genetic background. We also show there is no critical region defining the degree of phenotypic abnormalities in ATR-16 syndrome and this has important implications for genetic counselling.
- Published
- 2019
- Full Text
- View/download PDF
11. Hb Nouakchott [114(GH2)ProLeu; HBA1: c.344C > T], A Second and Third Case Described in Two Unrelated Dutch Families
- Author
-
Jacoline W. Brinkman, An K. Stroobants, Hanneke M. van der Straaten, Cornelis L. Harteveld, Kirsten M. Pondman, Academic Medical Center, and Laboratory for General Clinical Chemistry
- Subjects
0301 basic medicine ,Adult ,Male ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Hb Nouakchott ,Biology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,hemoglobinopathy ,Family ,Genetics (clinical) ,Aged ,Genetics ,Genetic Carrier Screening ,Biochemistry (medical) ,A hemoglobin ,Electrophoresis, Capillary ,Hematology ,Middle Aged ,medicine.disease ,Hemoglobinopathies ,030104 developmental biology ,Hemoglobinopathy ,Hemoglobin (Hb) variant ,030220 oncology & carcinogenesis ,Mutation (genetic algorithm) ,Female ,mutation - Abstract
We report two families, members of which are carriers of a hemoglobin (Hb) variant previously described as Hb Nouakchott [α114(GH2)Pro→Leu; HBA1: c.344C>T; p.Pro115Leu]. In the first family of Dutch origin, the proband, a 32-year-old male and his 65-year-old father, were both carriers of Hb Nouakchott. Of the second family we tested, only the proband, a 56-year-old Dutch female was a Hb Nouakchott carrier. Hematological analyses of these cases showed the anomaly behaves as a silent Hb variant without clinical consequences. The Hb variant remained unnoticed using high performance liquid chromatography (HPLC), while an additional peak was detected by capillary electrophoresis (CE). These independent findings of Hb Nouakchott indicate that this Hb variant might not be very rare, but simply remains under diagnosed depending on the Hb separation technique used
- Published
- 2018
12. Preconception carrier screening and prenatal diagnosis in thalassemia and hemoglobinopathies: challenges and future perspectives
- Author
-
Joanne Traeger-Synodinos and Cornelis L. Harteveld
- Subjects
Male ,medicine.medical_specialty ,thalassemia ,Thalassemia ,Population ,Genetic Carrier Screening ,Prenatal diagnosis ,sickle cell syndromes ,Preconception Care ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Genetics ,medicine ,Humans ,Genetic Testing ,Dna diagnosis ,Psychiatry ,education ,Intensive care medicine ,Molecular Biology ,health burden ,Genetic testing ,education.field_of_study ,prenatal diagnosis ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Hemoglobinopathies ,030220 oncology & carcinogenesis ,preconception carrier screening ,Molecular Medicine ,Female ,Carrier screening ,business ,030215 immunology - Abstract
Hemoglobinopathies constitute the most common severe monogenic disorders worldwide, with an increasing global burden each year. The benefit of applying programmes for preconception carrier screening, with the option of prenatal diagnosis, to minimize the incidence of new cases is recognized in many countries. Areas covered: The challenges associated with identifying carrier couples using hematology-based screening, along with DNA diagnosis and prenatal diagnosis were addressed, based on a literature search and the authors expertise. Expert commentary: The hemoglobinopathies are extremely heterogeneous at the haematological, molecular and clinical level, requiring appropriately equipped and staffed laboratories with experience to support comprehensive screening and diagnosis. However complete services with adequate infrastructure to address the associated technical challenges do not exist widely, especially in low-income countries that, coincidentally, are often those with the highest frequency of hemoglobinopathies in their population. Additionally, overcoming limited public awareness, education and absence of systematic dissemination of information also constitutes a challenge. This article aims to highlight these challenges and to evaluate potential future developments that may address at least some of them, focusing mainly on the technical challenges related to molecular diagnostics.
- Published
- 2017
13. Broader Spectrum ofβ-Thalassemia Mutations in Oman: Regional Distribution and Comparison with Neighboring Countries
- Author
-
Egbert Bakker, Suha M. Hassan, Cornelis L. Harteveld, and Piero C. Giordano
- Subjects
Genotype ,Oman ,Thalassemia ,Clinical Biochemistry ,Population ,Distribution (economics) ,beta-Globins ,Biology ,Gene Frequency ,medicine ,Humans ,Allele ,education ,Alleles ,Genetics (clinical) ,beta Gene mutation spectrum ,education.field_of_study ,business.industry ,beta-Thalassemia ,Biochemistry (medical) ,Exons ,Hematology ,medicine.disease ,Introns ,beta-thalassemia (beta-thal) ,Evolutionary biology ,Mutation ,business - Abstract
The objective of this study was to expand and study the molecular spectrum of β-thalassemia (β-thal) mutations in Oman by examining cases from seven different regions and comparing the prevalence with neighboring countries. A total of 446 cases of β hemoglobinopathies was obtained and analyzed to determine the frequency and distribution of the different β alleles. The molecular spectrum of β-thal in Oman revealed the presence of 32 mutations from different origins and 11 alleles are reported for the first time in the Omani population. The wide heterogeneous spectrum of β-thal mutations found can be associated with the history of trade and migration as well as the past domination from other countries. The presented data will facilitate the development of a comprehensive prevention strategy in Oman.
- Published
- 2015
14. Molecular basis of α-thalassemia
- Author
-
Cornelis L. Harteveld and Samaneh Farashi
- Subjects
0301 basic medicine ,Genotype ,Thalassemia ,Genetic counseling ,Genetic Counseling ,Biology ,medicine.disease_cause ,Asymptomatic ,Diagnosis, Differential ,03 medical and health sciences ,alpha-Globins ,alpha-Thalassemia ,medicine ,Animals ,Humans ,Molecular Biology ,Gene ,Genetic Association Studies ,Genetics ,Mutation ,Point mutation ,Disease Management ,Cell Biology ,Hematology ,medicine.disease ,Phenotype ,030104 developmental biology ,Genetic Loci ,Molecular Medicine ,medicine.symptom - Abstract
α-Thalassemia is an inherited, autosomal recessive, disorder characterized by a microcytic hypochromic anemia. It is one of the most common monogenic gene disorders in the world population. The clinical severity varies from almost asymptomatic, to mild microcytic hypochromic, and to a lethal hemolytic condition, called Hb Bart's Hydrops Foetalis Syndrome. The molecular basis are usually deletions and less frequently, point mutations affecting the expression of one or more of the duplicated α-genes. The clinical variation and increase in disease severity is directly related to the decreased expression of one, two, three or four copies of the α-globin genes. Deletions and point mutations in the α-globin genes and their regulatory elements have been studied extensively in carriers and patients and these studies have given insight into the α-globin genes are regulated. By looking at naturally occurring deletions and point mutations, our knowledge of globin-gene regulation and expression will continue to increase and will lead to new targets of therapy.
- Published
- 2017
15. Hereditary persistence of fetal hemoglobin in two patients with KLF1 haploinsufficiency due to 19p13.2-p13.12/13 deletion
- Author
-
Kirsten van Lom, Cornelis L. Harteveld, Ileana Cantú, Rianne Schaap, Sjaak Philipsen, Abdelhafid Natiq, Bella Banjanin, Nynke Gillemans, Abdelaziz Sefiani, Saaid Amzazi, Siham Chafai Elalaoui, Philippe A. Lysy, Cell biology, and Hematology
- Subjects
0301 basic medicine ,Genetics ,03 medical and health sciences ,030104 developmental biology ,Hereditary persistence of fetal hemoglobin ,Cancer research ,medicine ,KLF1 ,Gamma globulin ,Hematology ,Biology ,medicine.disease ,Haploinsufficiency - Published
- 2017
16. Characterization of Hb Calvino (HBB: c.406G > A): A New Silent β-Globin Gene Variant Found in Coexistence with α-Thalassemia in a Family of African Origin
- Author
-
Anna Ravani, Maria Marsella, Gian Luca Salvagno, Cornelis L. Harteveld, Bernadetta Dolcini, Piero C. Giordano, Alessandra Ferlini, and Caterina Borgna-Pignatti
- Subjects
Proband ,Heterozygote ,Hemoglobins, Abnormal ,Thalassemia ,(α-thal) ,angolan-Mozambican origin ,missense mutation ,α-Thalassemia ,β-globin variant ,Amino Acid Substitution ,Angola ,Child, Preschool ,Codon ,Fathers ,Female ,Gene Deletion ,Homozygote ,Humans ,Italy ,Severity of Illness Index ,Siblings ,alpha-Thalassemia ,beta-Globins ,Point Mutation ,Clinical Biochemistry ,Alpha-thalassemia ,Biology ,Loss of heterozygosity ,Hemoglobins ,medicine ,Missense mutation ,Child ,Preschool ,Gene ,Genetics (clinical) ,Genetics ,Transition (genetics) ,Point mutation ,Biochemistry (medical) ,Hematology ,medicine.disease ,Abnormal - Abstract
We report a new silent β-globin gene variant found in a family from Angola living in the north eastern Italian city of Ferrara. The probands, two young sisters, presented with hematological parameters compatible with a β-thalassemia (β-thal) minor but with normal Hb A2 levels and normal hemoglobin (Hb) separation on high performance liquid chromatography (HPLC). Molecular analyses revealed a homozygosity for the common –α3.7 (rightward) deletion and heterozygosity for a novel transition (GCT > ACT) at codon 135 of the β-globin gene, leading to an Ala → Thr single amino acid substitution that was inherited from the healthy father.
- Published
- 2014
17. Hemoglobin analyses in the Netherlands reveal more than 80 different variants including six novel ones
- Author
-
Cornelis L. Harteveld, Barend Delzenne, Fatima Ait Ichou, Els Clifford, Jeffrey Berghuis, Joke Groen, Martijn Veldthuis, An K. Stroobants, Rob van Zwieten, Landsteiner Laboratory, and Laboratory for General Clinical Chemistry
- Subjects
Hemolytic anemia ,Thalassemia ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Increased oxygen affinity ,beta-Globins ,High-performance liquid chromatography ,Hemoglobins ,Capillary electrophoresis ,alpha-Globins ,medicine ,Humans ,Genetics (clinical) ,Chromatography, High Pressure Liquid ,Netherlands ,Chromatography ,Isoelectric focusing ,Chemistry ,Biochemistry (medical) ,Electrophoresis, Capillary ,Hematology ,medicine.disease ,Molecular biology ,Hemoglobinopathies ,Hemoglobinopathy ,Mutation ,Hemoglobin - Abstract
More than 20 000 blood samples of individuals living in The Netherlands and suspected of hemolytic anemia or diabetes were analyzed by high resolution cation exchange high performance liquid chromatography (HPLC). Besides common disease-related hemoglobins (Hbs), rare variants were also detected. The variant Hbs were retrospectively analyzed by capillary zone electrophoresis (CZE) and by isoelectric focusing (IEF). For unambiguous identification, the globin genes were sequenced. Most of the 80 Hb variants detected by initial screening on HPLC were also separated by capillary electrophoresis (CE), but a few variants were only detectable with one of these methods. Some variants were unstable, had thalassemic properties or increased oxygen affinity, and some interfered with Hb A2 measurement, detection of sickle cell Hb or Hb A1c quantification. Two of the six novel variants, Hb Enschede (HBA2: c.308G > A, p.Ser103Asn) and Hb Weesp (HBA1: c.301C > T, p.Leu101Phe), had no clinical consequences. In contrast, two others appeared clinically significant: Hb Ede (HBB: c.53A > T, p.Lys18Met) caused thalassemia and Hb Waterland (HBB: c.428C > T, pAla143Val) was related to mild polycytemia. Hb A2-Venlo (HBD: c.193G > A, p.Gly65Ser) and Hb A2-Rotterdam (HBD: c.38A > C, p.Asn13Thr) interfered with Hb A2 quantification. This survey shows that HPLC analysis followed by globin gene sequencing of rare variants is an effective method to reveal Hb variants
- Published
- 2014
18. Advances in technologies for screening and diagnosis of hemoglobinopathies
- Author
-
Cornelis L. Harteveld and J. Traeger-Synodinos
- Subjects
Electrophoresis ,Thalassemia ,Clinical Biochemistry ,Prenatal diagnosis ,Biology ,medicine.disease_cause ,Mass Spectrometry ,DNA sequencing ,Hemoglobins ,symbols.namesake ,Drug Discovery ,medicine ,Humans ,Multiplex ligation-dependent probe amplification ,Chromatography, High Pressure Liquid ,Oligonucleotide Array Sequence Analysis ,Genetics ,Sanger sequencing ,Mutation ,Point mutation ,Biochemistry (medical) ,DNA ,Sequence Analysis, DNA ,medicine.disease ,Hemoglobinopathies ,symbols ,DNA microarray - Abstract
Hemoglobinopathies constitute the most common monogenic disorders worldwide, caused by mutations in the globin genes that synthesize the globin chains of hemoglobin. Synthesis may be reduced (thalassemia) or underlie abnormal hemoglobins. Mutation interactions produce a wide range of disorders. For neonatal and antenatal screening, identification of affected newborns or carriers is achieved by hematological tests. DNA analysis supports definitive diagnosis, and additionally facilitates prenatal diagnosis procedures. Most methods used today have been developed over several decades, with few recent advances in hematology methods. However, DNA methods evolve continuously. With global migration and multiethnic societies the trend is from targeted, population-specific methods towards generic methods, such as Sanger sequencing (point mutations) and multiplex ligation probe amplification (deletions). DNA microarrays constitute an advanced DNA method for some mutation categories. The newest DNA technology is next-generation sequencing. Although not completely ready for routine use currently, next-generation sequencing may soon become a reality for some hemoglobin diagnostic laboratories.
- Published
- 2014
19. Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease
- Author
-
Bart J. Biemond, Veronica van der Land, Cornelis L. Harteveld, Harriët Heijboer, Marjolein Peters, Karin Fijnvandraat, Other departments, Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, Clinical Haematology, General Paediatrics, and ACS - Amsterdam Cardiovascular Sciences
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Anemia, Sickle Cell ,Disease ,von Willebrand factor ,Risk Assessment ,Cohort Studies ,chemistry.chemical_compound ,Von Willebrand factor ,Lactate dehydrogenase ,hemic and lymphatic diseases ,Genotype ,medicine ,Humans ,Endothelial dysfunction ,Child ,Prospective cohort study ,Stroke ,von Willebrand factor propeptide ,biology ,business.industry ,Sickle cell disease ,Hematology ,medicine.disease ,Pulmonary hypertension ,Phenotype ,chemistry ,Pediatric hematology/oncology ,Child, Preschool ,Immunology ,Disease Progression ,biology.protein ,Female ,Endothelium, Vascular ,business - Abstract
In adult patients with sickle cell disease two distinct subphenotypes have previously been defined: patients with the viscosity-vaso-occlusion subphenotype (VVO) suffer mainly from vaso-occlusive pain crises and have a relatively high hemoglobin concentration. Patients classified as the hemolysis-endothelial dysfunction subphenotype (HED) suffer from stroke and pulmonary hypertension and have an elevated concentration of lactate dehydrogenase. However, this classification is not possible in children due to low rates of complications. We used laboratory markers to classify children into the two subphenotypes, and measured vWF and vWF propeptide as markers of endothelial dysfunction. We included 106 children with sickle cell disease (mean age 8.7 years), 74 (70%) with HbSS/HbSβ° genotype and 32 (30%) with HbSC/HbSβ+ genotype. vWF and vWF propeptide were significantly elevated in patients with sickle cell disease; this was more pronounced in patients with the HbSS/HbSβ° genotype. Patients with the HED subphenotype had higher levels of vWF propeptide, and a trend towards higher levels of vWF compared to those with the VVO subphenotype. We demonstrated that even young children in a stable clinical condition show signs of persistent endothelial dysfunction. A prospective study should demonstrate whether elevated levels of vWF and its propeptide are associated with an increased risk of complications specific for the HED subphenotype.
- Published
- 2013
- Full Text
- View/download PDF
20. Expression of the Human Alpha-Globin Cluster in the Absence of the Major Regulatory Element Mcs-R2
- Author
-
Douglas R. Higgs, Cornelis L. Harteveld, Damien J. Downes, James O.J. Davies, Eduard J. van Beers, and Mohsin Badat
- Subjects
Genetics ,Proband ,Immunology ,Alpha (ethology) ,Locus (genetics) ,Cell Biology ,Hematology ,Alpha-thalassemia ,Biology ,medicine.disease ,Biochemistry ,Chromosome 16 ,Genotype ,medicine ,Allele ,Gene - Abstract
The alpha-globin genes are located in the subtelomeric region of the short arm of chromosome 16. Expression of each allele is controlled by 4 distal cis-acting enhancers (MCS-R1-4) located 48, 40, 33 and 10kb upstream of the duplicated structural alpha genes . Experimental and clinical studies have shown that R1 and R2 are the most important enhancers of alpha-globin production. Here we present an individual with alpha thalassemia who inherited one copy of chromosome 16 from which both alpha genes have been deleted (--SEA). This individual's other copy of chromosome 16 harbours a small deletion of R2. Thus all alpha-globin expression in this individual originates from one copy of the alpha cluster in which R1 drives expression of the two alpha-globin genes in cis. Remarkably, this patient maintains a relatively normal degree of oxygenation despite a severe degree of alpha thalassemia. This female patient was born in Surinam and her mother and father were of Indian and Indonesian origins respectively. She most recently presented, aged 26 yrs, with tiredness and shortness of breath on exertion. She had no previously diagnosed medical conditions, but had received two blood transfusions as a child, both prompted by concurrent infections. Her growth and development were normal. She had suffered one miscarriage at 13 weeks gestation aged 25 yrs. There was nothing of note in the family history and the patient is currently employed as a clerical worker. Cardiovascular examination was normal with no hepatosplenomegaly. Her CBC was consistent with HbH disease, with a Hb of 73g/L, Hct 25%, MCV 45fl, MCH 13.2pg with a blood film showing marked microcytosis anisopoikilocytosis, target cells and 30.7% HbH inclusions on Brilliant Cressyl Blue staining. HPLC showed evidence of a fast-moving band, HbA 88.4% and HbA2 1.3%, HbE 5.1%. MLPA analysis showed that the father and proband both carried heterozygous deletions of R2, and the mother and proband both carried the --SEA deletion on one allele. Due to the severity of the anaemia and the striking red cell indices it was highly likely that she had intact regulatory elements in cis with the --SEA deletion on one allele, and on the other, a regulatory network missing R2 lying upstream of the two intact alpha-globin genes To investigate this further, CD34+ cells were extracted from the patient's peripheral blood and differentiated using a liquid culture system (Trakarnsanga et al. Nature Comms. 2017). The alpha/non-alpha-globin synthetic ratio of mRNA as measured by qPCR at peak globin-production was markedly reduced compared to WT cells and those of a patient carrying the --SEA deletion on one allele alone: WT 1.26, SEA 0.65, Patient 0.11. The upstream enhancers are associated with regions of open chromatin that can be detected by chromatin accessibility assays. To see whether the deletion of R2 had caused new regulatory elements to appear or whether accessibility of the existing elements was altered, ATAC-seq was performed on Day 13 of differentiation. This showed a reduction in the peak at R2 in keeping with its deletion on one allele, but showed no change in the peak height of R1 compared to that in the individual with the --SEA deletion alone or WT. To assess chromatin interactions across the domain Capture-C, a sensitive assay to detect interactions between selected regions of chromatin, was performed (Davies et al. Nature Methods 2016). Compared to WT, when capturing from the alpha-globin promoters interactions with R1, R3 and R4 were observed with no interactions with R2 detected, in keeping with the hypothesised distribution of deletions. No interactions in trans between the intact R2 and alpha-globin genes were detected. Previous cases of deletions of the upstream alpha-globin regulatory element have either involved deletions of the regulatory elements on one allele only, or involved both alleles but with a full complement of alpha genes. Our findings show that whilst a severe HbH phenotype was observed, it is possible to maintain transfusion independence with only R1, R3, R4 and two alpha-globin genes. Considering the ATAC-seq and Capture-C findings, as well as comparison with the homologous locus in mouse it is likely that the bulk of regulation in this patient occurs via R1. The observed phenotype is consistent with redundancy within the regulatory elements of the alpha gene locus, which may enable continued expression of key cell-specific genes in the event of adverse genotypic events. Disclosures van Beers: RR Mechatronics: Research Funding; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Pfizer: Research Funding.
- Published
- 2018
21. A Mosaic Expression of a Hb J-Amiens (HBB: c.54G > T; p.Lys18Asn) and its Interference with Hb A1cAnalysis
- Author
-
Koen Desmet, Toon Schiemsky, Lieve Van Hoovels, Davy Kieffer, Cornelis L. Harteveld, and Marion Phylipsen
- Subjects
Erythrocyte Indices ,Genotype ,DNA Mutational Analysis ,Clinical Biochemistry ,Mutant ,Gene Expression ,beta-Globins ,Biology ,medicine.disease_cause ,Capillary electrophoresis ,medicine ,Humans ,Codon ,Genetics (clinical) ,Glycated Hemoglobin ,Hemoglobin J ,Gel electrophoresis ,Mutation ,Biochemistry (medical) ,Wild type ,Hematology ,Middle Aged ,medicine.disease ,Molecular biology ,Hemoglobinopathies ,Phenotype ,Hemoglobinopathy ,Amino Acid Substitution ,Biochemistry ,Female ,Hemoglobin - Abstract
We report the case of a 56-year-old Caucasian woman in whom hemoglobinopathy screening was triggered following an aberrant Hb A1c analysis. Preliminary diagnosis of the hemoglobin (Hb) variant was obtained through cation exchange high performance liquid chromatography (HPLC) and gel electrophoresis. DNA analysis confirmed the presence of Hb J-Amiens [β17(A14)Lys→Asn; HBB: c.[54G > C or 54G > T)]. However, an unbalanced ratio between wild type and mutant signal after direct sequencing and a lower than expected percentage of this Hb variant led to the suggestion of a mosaic expression. Furthermore, different methods [capillary zone electrophoresis (CZE), cation exchange HPLC and boronate affinity] were tested to study the possible interference of this variant with Hb A1c measurements. These investigations showed a clinically relevant difference between the methods tested. Hb A1c analysis may lead to the discovery of new Hb variants or mosaicism for previously described Hb variants. This may have genetic consequences for the offspring of carriers and brings about the question of partner testing.
- Published
- 2015
22. State of the art and new developments in molecular diagnostics for hemoglobinopathies in multiethnic societies
- Author
-
Cornelis L. Harteveld
- Subjects
Male ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Genetic Counseling ,Prenatal diagnosis ,Anemia, Sickle Cell ,beta-Globins ,Biology ,DNA sequencing ,alpha-Globins ,alpha-Thalassemia ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Multiplex ligation-dependent probe amplification ,Pathology, Molecular ,DNA Primers ,Oligonucleotide Array Sequence Analysis ,Genetics ,beta-Thalassemia ,Biochemistry (medical) ,Breakpoint ,Hematology ,General Medicine ,Molecular diagnostics ,medicine.disease ,Hemoglobinopathy ,Gene chip analysis ,Female ,Primer (molecular biology) ,Multiplex Polymerase Chain Reaction - Abstract
SUMMARY For detecting carriers of thalassemia traits, the basic part of diagnostics consists of measurement of the hematological indices followed by mostly automatic separation and measurement of the Hb fractions, while direct Hb separation either on high pressure liquid chromatography or capillary electrophoresis is sufficient to putatively identify carriers of the common Hb variants like HbS, C, E, D, and O-Arab. A putative positive result is reported together with an advice for parents, partner, or family analysis. For couples, presumed at-risk confirmation at the DNA level is essential. In general, this part of diagnostics is done in specialized centers provided with sufficient experience and the technical tools needed to combine hematological and biochemical interpretation with identification of the mutations at the molecular level. State-of-the-art tools are usually available in centers that also provide prenatal diagnosis and should consist of gap-PCR for the common deletions, direct DNA sequencing for all kind of point-mutations and the capacity to uncover novel or rare mutations or disease mechanisms. New developments are MLPA for large and eventually unknown deletion defects and microarray technology for fine mapping and primer design for breakpoint analysis. Gap-PCR primers designed in the region flanking the deletion breakpoints can subsequently be used to facilitate carrier detection of uncommon deletions in family members or isolated populations in laboratories where no microarray technology or MLPA is available.
- Published
- 2013
23. Molecular analysis of complex cases of alpha- and beta-thalassemia in Mexican mestizo patients with microcytosis and hypochromia reveals two novel alpha(0)-thalassemia deletions --(Mex1) and --(Mex2)
- Author
-
Cornelis L. Harteveld, Josefina Yoaly Sánchez-López, B. Ibarra, Francisco Javier Perea-Díaz, E. I. de-la-Cruz-Salcedo, Anahí González-Mercado, and L. C. Rizo-de-la-Torre
- Subjects
0301 basic medicine ,Male ,Thalassemia ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Biology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,alpha-Thalassemia ,medicine ,Humans ,Multiplex ligation-dependent probe amplification ,Allele ,Gene ,Mexico ,Alleles ,Sequence Deletion ,Genetics ,Glycated Hemoglobin ,Mutation ,Anemia, Hypochromic ,Base Sequence ,Microcytosis ,Biochemistry (medical) ,beta-Thalassemia ,Beta thalassemia ,Hematology ,General Medicine ,medicine.disease ,Molecular biology ,microcytosis ,030104 developmental biology ,complex - and -thalassemia genotypes ,Hypochromia ,Female ,alpha-globin deletion ,030215 immunology - Abstract
Introduction Alpha-thalassemia (α-thal) is a common monogenic disorder worldwide. In mixed ethnic populations, α-thal and beta-thalassemia (β-thal) can be expected, sometimes giving complex phenotypes, which without molecular analysis are not easily explained. We performed the molecular identification of α- and β-thal alleles in 51 Mexican patients with microcytosis, hypochromia, and normal or low levels of HbA2 . Methods Common deletional alleles (-α(3.7) , -α(4.2) , - -(SEA) , - -(MED) , - -(FIL) , - -(THAI) , -α(20.5) ) and α-triplication were studied by gap-PCR and nondeletional alleles (α(IVSI) ((-5nt)) , α2 (NcoI) , α1 (NcoI) ) by ARMS. β-thal alleles Cd39 (C>T), IVS1:1 (G>A), IVS1:110 (G>A), and Spanish δβ-thal were also investigated. DNA sequencing was performed on HBA2, HBA1, and HBB genes. Negative samples were subjected to MLPA. Results In 35 subjects, we identified the mutations, -α(3.7) , - -(SEA) , - -(FIL) , α(IVSI) ((-5nt)) , and ααα(anti3.7) and two novel deletion alleles - -(Mex1) (6.8-8.9 kb) and - -(Mex2) (77.6-135.7 kb). Four individuals also had a β-thal allele (Cd39/IVS1:110). No α-thal alleles were observed in 16 subjects, but three had a β-thal mutation Cd39, IVS1:110, and Spanish δβ-thal. Conclusion α-thal is relatively common in Mexican patients, the combination with β-thal is sometimes unexpected, and this underlines the importance of performing molecular analysis for both α- and β-genes defects in patients showing microcytic hypochromic anemia.
- Published
- 2016
24. Hb Olivet (HBA1: C.40G > A; p.Ala14Thr), a Novel Silent Hemoglobin Variant in Two Families of Distinct Origin
- Author
-
Serge Pissard, Piero C. Giordano, Eric Legac, Anna M H Korver, Gideon W.A. Lansbergen, Cornelis L. Harteveld, Inge L Pardijs, Florens G. A. Versteegh, and Jean Riou
- Subjects
0301 basic medicine ,Proband ,Male ,medicine.medical_specialty ,Heterozygote ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Biology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Abnormal hemoglobin (Hb) ,Family ,Child ,Mean corpuscular volume ,Genetics (clinical) ,Genetic Association Studies ,Netherlands ,Genetics ,Suriname ,medicine.diagnostic_test ,Portugal ,Microcytosis ,Low ferritin ,Biochemistry (medical) ,Hemoglobin variants ,Hb Olivet ,Hematology ,Iron Deficiencies ,Middle Aged ,medicine.disease ,thalassemia (-thal) ,Hemoglobinopathies ,030104 developmental biology ,Endocrinology ,Mutation ,Female ,Hemoglobin ,France ,030215 immunology - Abstract
We report two families, members of which are carriers of a novel hemoglobin (Hb) variant that was named Hb Olivet [α13(A11)Ala→Thr (α1) (GCC ACC); HBA1: c.40G A; p.Ala14Thr]. The analysis of these cases allowed a clear description of this anomaly that behaves as a silent Hb. In the first family, of Portuguese ethnicity living in France, the proband, a 24-year-old male and his 57-year-old mother, both appeared to be carriers. The son presented with borderline mean corpuscular volume (MCV), while the mother was normocytic and normochromic. Hemoglobin separation on capillary electrophoresis (CE) was normal, while a slightly asymmetric peak was observed on high performance liquid chromatography (HPLC). In a second family, originally from Surinam but living in The Netherlands, the proband, a 6-year-old girl, showed a mild microcytosis at low ferritin levels. The abnormal Hb was inherited from the mother who was clearly iron depleted, was not present in the sister and brother of the proband. The microcytic hypochromic anemia was only shown in two out of a total of four carriers. It therefore seems likely that iron depletion is causative as two carriers are completely normal. Characterization and genotype/phenotype correlation are briefly described.
- Published
- 2016
25. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach
- Author
-
Petros Papadopoulos, Swee Lay Thein, Kenneth R. Peterson, Iris Schrijver, Kamran Moradkhani, Sonja Pavlovic, Barnaby Clark, James D. Hoyer, Raymond E. Tully, Philippe Joly, Alain Francina, D J Anstee, Lucia Perseu, Ross C. Hardison, Emmanuel Kanavakis, Halyna Fedosyuk, Stephan Menzel, Douglas R. Higgs, Maja Stojiljkovic, Henri Wajcman, Belinda Giardine, Stefania Satta, Belinda K. Singleton, Marianthi Georgitsi, John S. Waye, Webb Miller, George P. Patrinos, Branka Zukic, Sjaak Philipsen, Milena Radmilovic, J. Traeger-Synodinos, Flávia C. Costa, Donna Maglott, David H.K. Chui, Monica V.E. Gallivan, Panagoula Kollia, Martin Jarvis, A. Nazli Basak, Cornelis L. Harteveld, Adamantia Papachatzopoulou, Richard J. Gibbons, Joseph Borg, John Old, Manoussos N. Papadakis, Claudia Wiemann, Renzo Galanello, Piero C. Giordano, Paula Faustino, Cathy Riemer, Alex E. Felice, and Takahito Wada
- Subjects
thalassemia ,Molecular Sequence Data ,Human genetic variation ,Computational biology ,Biology ,Genome ,Article ,Hemoglobins ,03 medical and health sciences ,0302 clinical medicine ,Documentation ,Databases, Genetic ,Human Genome Project ,Genetic variation ,Genetics ,medicine ,locus-specific databases ,Data Mining ,Humans ,microattribution ,Genetic variability ,Promoter Regions, Genetic ,hemoglobinopathies ,030304 developmental biology ,Publishing ,0303 health sciences ,Base Sequence ,Genome, Human ,Genetic Variation ,DNA ,medicine.disease ,Doenças Genéticas ,Hemoglobinopathies ,Hemoglobinopathy ,030220 oncology & carcinogenesis ,Mutation ,Mutation (genetic algorithm) ,Human genome - Abstract
We developed a series of interrelated locus-specific databases to store all published and unpublished genetic variation related to these disorders, and then implemented microattribution to encourage submission of unpublished observations of genetic variation to these public repositories 1. A total of 1,941 unique genetic variants in 37 genes, encoding globins (HBA2, HBA1, HBG2, HBG1, HBD, HBB) and other erythroid proteins (ALOX5AP, AQP9, ARG2, ASS1, ATRX, BCL11A, CNTNAP2, CSNK2A1, EPAS1, ERCC2, FLT1, GATA1, GPM6B, HAO2, HBS1L, KDR, KL, KLF1, MAP2K1, MAP3K5, MAP3K7, MYB, NOS1, NOS2, NOS3, NOX3, NUP133, PDE7B, SMAD3, SMAD6, and TOX) are currently documented in these databases with reciprocal attribution of microcitations to data contributors. Our project provides the first example of implementing microattribution to incentivise submission of all known genetic variation in a defined system. It has demonstrably increased the reporting of human variants and now provides a comprehensive online resource for systematically describing human genetic variation in the globin genes and other genes contributing to hemoglobinopathies and thalassemias. The large repository of previously reported data, together with more recent data, acquired by microattribution, demonstrates how the comprehensive documentation of human variation will provide key insights into normal biological processes and how these are perturbed in human genetic disease. Using the microattribution process set out here, datasets which took decades to accumulate for the globin genes could be assembled rapidly for other genes and disease systems. The principles established here for the globin gene system will serve as a model for other systems and the analysis of other common and/or complex human genetic diseases.
- Published
- 2016
26. Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis
- Author
-
Cornelis L. Harteveld, Warsha A. Kanhai, Supawadee Yamsri, Marion Phylipsen, Egbert Bakker, Diahann T. S. L. Jansen, Supan Fucharoen, Emmely E. Treffers, Piero C. Giordano, and Elles M. J. Boon
- Subjects
Gynecology ,0303 health sciences ,medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics and Gynecology ,Beta thalassemia ,Chorionic villus sampling ,Prenatal diagnosis ,Single-nucleotide polymorphism ,Biology ,medicine.disease ,Melting curve analysis ,3. Good health ,law.invention ,Andrology ,03 medical and health sciences ,0302 clinical medicine ,Cell-free fetal DNA ,law ,medicine ,Allele ,Genetics (clinical) ,Polymerase chain reaction ,030304 developmental biology - Abstract
Objective The aim of this study was to develop a pyrophosphorolysis-activated polymerization (PAP) assay for non-invasive prenatal diagnosis (NIPD) of β-thalassemia major and sickle-cell disease (SCD). PAP is able to detect mutations in free fetal DNA in a highly contaminating environment of maternal plasma DNA. Methods Pyrophosphorolysis-activated polymerization primers were designed for 12 informative SNPs, genotyped by melting curve analysis (MCA) in both parents. The PAP assay was tested in a series of 13 plasma DNA samples collected from pregnant women. A retrospective NIPD was performed in a couple at risk for SCD. Results All PAP reactions were optimized and able to detect 97% wildtype gDNA. In all 13 cases, the paternal allele was detected by PAP in maternal plasma at 10 to 18 weeks of gestation. For the couple at risk, PAP showed presence of the normal paternal SNP allele in maternal plasma, which was confirmed by results of the chorionic villus sampling analysis. Conclusions In contrast to other methods used for NIPD, the combined PAP and MCA analysis detecting the normal paternal allele is also applicable for couples at risk carrying the same mutation, provided that a previously born child is available for testing to determine the linkage to the paternal SNPs. © 2012 John Wiley & Sons, Ltd.
- Published
- 2012
27. A novel α0-thalassemia deletion in a Greek patient with HbH disease and β-thalassemia trait
- Author
-
Martijn van der Kraan, Mariska Geerts, Alexandra Stamoulakatou, Greet Bakker, J. Traeger-Synodinos, Emmanuel Kanavakis, Piero C. Giordano, Cornelis L. Harteveld, Markissia Karagiorga, Marion Phylipsen, and Peter van Delft
- Subjects
Genetics ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Mutation ,Hematology ,Anemia ,Thalassemia ,Breakpoint ,General Medicine ,Biology ,medicine.disease ,medicine.disease_cause ,Molecular biology ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Multiplex ligation-dependent probe amplification ,Allele ,Comparative genomic hybridization - Abstract
Objectives: To determine the molecular basis in a Greek child suspected of having HbH disease and β-thalassemia trait. Methods: Standard hematology, Hb electrophoresis, and HPLC. Multiplex ligation-dependent probe amplification (MLPA), direct sequencing, and breakpoint characterization by NimbleGen fine-tiling array analysis. Results: The index patient showed a moderate microcytic hypochromic anemia with normal ZPP and elevated HbA2, indicative for β-thalassemia trait. However, the moderate microcytic hypochromic anemia along with the observation of HbH inclusions in occasional red blood cells suggested a coexisting α-thalassemia. Molecular analysis indicated that the propositus inherited the β+-thalassemia mutation IVS2-745 (c>g) and a novel α0-thalassemia deletion from the mother, and the common non-deletion α-thalassemia allele α2(−5nt)α from the father. The α0-thalassemia deletion, named - -BGS, is approximately 131.6 kb in length. It removes the major regulatory elements along with the functional α-globin genes but leaves the theta-gene intact. Conclusions: The compound interaction of a β-thalassemia defect along with a single functional α-globin gene is quite rare. Although patients with HbH/β-thal and simple HbH disease have comparable levels of Hb, the absence of free β-globin chains and thus detectable non-functional HbH means that in HbH/β-thal, the levels of functional Hb are higher, resulting in a better compensated functional anemia. Rare large deletions as the one described here remain undetected by gap-PCR in routine molecular screening. The introduction of MLPA as a diagnostic screening tool may improve laboratory diagnostics for these defects. The use of NimbleGen fine-tiling arrays may give additional information about the precise location of breakpoints.
- Published
- 2012
28. Fine-Tiling Array CGH to Improve Diagnostics for alpha- and beta-Thalassemia Rearrangements
- Author
-
Ingrid P. Vogelaar, Cornelis L. Harteveld, Piero C. Giordano, Rianne Schaap, Jeetindra R A Balak, Supan Fucharoen, Attawut Chaibunruang, Egbert Bakker, Johan T. den Dunnen, Marion Phylipsen, and Yavuz Ariyurek
- Subjects
thalassemia ,Genetics and epigenetic pathways of disease [NCMLS 6] ,Thalassemia ,DNA Mutational Analysis ,beta-Globins ,Biology ,breakpoint analysis ,Polymerase Chain Reaction ,Chromosome Breakpoints ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,alpha-Globins ,alpha-Thalassemia ,arrayCGH ,Genetics ,medicine ,Humans ,Multiplex ,Multiplex ligation-dependent probe amplification ,Genetics (clinical) ,DNA Primers ,Oligonucleotide Array Sequence Analysis ,Sequence Deletion ,030304 developmental biology ,Gene Rearrangement ,Comparative Genomic Hybridization ,0303 health sciences ,Tiling array ,Oligonucleotide ,beta-Thalassemia ,Breakpoint ,Exons ,medicine.disease ,3. Good health ,MLPA ,PCR ,chemistry ,030220 oncology & carcinogenesis ,DNA ,Comparative genomic hybridization - Abstract
Item does not contain fulltext Implementation of multiplex ligation-dependent probe amplification (MLPA) for thalassemia causing deletions has lead to the detection of new rearrangements. Knowledge of the exact breakpoint sequences should give more insight into the molecular mechanisms underlying these rearrangements, and would facilitate the design of gap-PCRs. We have designed a custom fine-tiling array with oligonucleotides covering the complete globin gene clusters. We hybridized 27 DNA samples containing newly identified deletions and nine positive controls. We designed specific primers to amplify relatively short fragments containing the breakpoint sequence and analyzed these by direct sequencing. Results from nine positive controls showed that array comparative genomic hybridization (aCGH) is suitable to detect small and large rearrangements. We were able to locate all breakpoints to a region of approximately 2 kb. We designed breakpoint primers for 22 cases and amplification was successful in 19 cases. For 12 of these, the exact locations of the breakpoints were determined. Seven of these deletions have not been reported before. aCGH is a valuable tool for high-resolution breakpoint characterization. The combination of MLPA and aCGH has lead to relatively cheap and easy to perform PCR assays, which might be of use for laboratories as an alternative for MLPA in populations where only a limited number of specific deletions occur with high frequency.
- Published
- 2012
- Full Text
- View/download PDF
29. Towards a Prevention Program for β-Thalassemia. The Molecular Spectrum in East Java, Indonesia
- Author
-
Marian C. Shanty Larasati, Piero C. Giordano, Pratika Yuhyi Hernanda, Cornelis L. Harteveld, Sentot Mustajab Soeatmadji, Luluk Tursilowati, Sandra G.J. Arkesteijn, and I. Dewa Gede Ugrasena
- Subjects
Male ,Genetics ,Genotype ,Geography ,Thalassemia ,DNA Mutational Analysis ,beta-Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Prevalence ,beta-Globins ,Hematology ,Biology ,medicine.disease ,Cohort Studies ,Gene Frequency ,Indonesia ,Homogeneous ,Mutation ,Cohort ,medicine ,Humans ,Female ,Genetics (clinical) - Abstract
Defining the spectrum of specific thalassemia mutations is an important issue when planning prevention programs in large multi ethnic countries as is Indonesia. In a first attempt to define the prevalence of the common mutations in East Java we selected a cohort of 17 transfusion-dependent patients attending the Dr. Soetomo Hospital, Surabaya, Indonesia. After basic diagnostics we performed direct DNA sequencing for all β-globin genes. The results obtained on 34 independent chromosomes revealed the following prevalence rates: c.79 GA p. Glu27Lys (Hb E) 47.0%; c.92+5GC (IVS-I-5 GC) 20.6%; c.109_110 delC p.Pro37Leu fs X7 [codon 35 (-C)] 17.6%; c.46del T p.Trp16Gly fsX4 [codon 15 (-T)] 5.9%; c.126_129delCTTT p. Phe42Leu fs X19 (codons 41/42) 2.9%; c.316-197 CT [IVS-II-654 (CT)] 2.9%; c*112 AG (PolyA) 2.9%. Our preliminary results show that the distribution of the prevalent mutations in our cohort is quite homogeneous but with different forms than previously reported. This indicates that more studies on a larger scale and in different geographical areas are needed to refine our provisional results and to characterize the molecular background of the disease in the whole country.
- Published
- 2011
30. Occurrence of common and rare δ-globin gene defects in two multiethnic populations: thirteen new mutations and the significance of δ-globin gene defects in β-thalassemia diagnostics
- Author
-
Monica V.E. Gallivan, Cornelis L. Harteveld, Marion Phylipsen, Piero C. Giordano, and Sandra G.J. Arkesteijn
- Subjects
Genetics ,Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,General Medicine ,Biology ,Reference laboratory ,medicine.disease ,Asymptomatic ,Molecular analysis ,Abnormal hemoglobin ,Polymorphism (computer science) ,medicine ,Globin gene ,medicine.symptom ,Gene - Abstract
INTRODUCTION The aim of this review is to study the frequency of common and the occurrence of rare and novel mutations of the delta-globin gene and of Hb Lepore defects that might interfere with thalassemia diagnostics and to report the rationale of HbA2 estimation in the presence of delta- or alpha-gene mutations. METHODS A total of 135 cases suspected to have a delta-globin gene defect collected in a diagnostic center in the USA and in a reference laboratory in the Netherlands were characterized by molecular analysis. RESULTS Hb B2 was found at a frequency of at least 0.5% in the USA and 0.87% in the Netherlands. Known variants such as Hb A2-Babinga, Hb A2-Sphakia, Hb A2-Fitzroy, Hb A2-Flatbush, Hb A2-NYU, Hb A2-Grovetown, HbA2-Yialousa, Hb A2-Indonesia and several delta-thalassemia mutations were found together with 13 new mutations and two new polymorphisms, while Hb Lepores were regularly observed. CONCLUSION HbA2 mutations either structurally stable and visible or undetectable because of a thalassemia effect or instability are clinically asymptomatic but may compromise the diagnosis of beta-thalassemia minor. Stable mutations result in two HbA2 fractions of about half of the expected value. Expression defects are undetectable as a protein fraction but reduce the amount of HbA2 by half.
- Published
- 2010
31. Codon 24 (TAT>TAG) and Codon 32 (ATG>AGG) (Hb Rotterdam): Two Novel α2 Gene Mutations Associated with Mild α-Thalassemia Found in the Same Family After Newborn Screening
- Author
-
Marelle J. Bouva, Piero C. Giordano, Annemarie M.S. Joosten, Peter van Delft, Cornelis L. Harteveld, Marjon H. Cnossen, Tineke E. Hakvoort, Sandra G.J. Arkesteijn, John S. Waye, Cees A.M. Jansen, and Margreet Bakker-Verweij
- Subjects
Adult ,Proband ,Hemoglobins, Abnormal ,Thalassemia ,Clinical Biochemistry ,Population ,Gene mutation ,Biology ,Neonatal Screening ,alpha-Globins ,alpha-Thalassemia ,Genotype ,medicine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Codon ,Transversion ,education ,Genetics (clinical) ,Family Health ,Genetics ,education.field_of_study ,Point mutation ,Biochemistry (medical) ,Infant, Newborn ,Hematology ,Middle Aged ,medicine.disease ,Stop codon ,Pedigree ,Mutation ,Female ,Anemia alpha-Thalassemia (alpha-thal) Newborn screening Prevention disease - Abstract
We report two novel alpha 2-globin gene mutations found in the same Surinamese family. The proband, a newborn presenting during neonatal screening with 21.3% Hb Bart's (gamma 4), proved to be a carrier of the common -alpha(3.7) deletion and a novel codon 32 (ATG>AGG) transversion that we named Hb Rotterdam. The father carried the same point mutation with borderline hemoglobin (Hb), MCV and low MCH values. The mother presented with a significant microcytic hypochromic anemia and also carried the -alpha(3.7) deletion and a second novel TAT>TAG transversion generating a stop codon at position 24. Shortly thereafter, Hb Rotterdam was again found in two unrelated adult females and in a Canadian newborn, all of African origin, suggesting that Hb Rotterdam could be a frequently occurring alpha(T) determinant in the Black population. Screening and characterization of the mutations, phenotype/genotype correlation and the issue of reporting newborn carriers of alpha-thalassemia (alpha-thal) are discussed.
- Published
- 2010
32. Extended Molecular Spectrum of β- and α-Thalassemia in Oman
- Author
-
Ali Jaffer Mohammed, Cornelis L. Harteveld, Anna Rajab, Suha M. Hassan, Fatma Jaffer Al-Lawatiya, Piero C. Giordano, and Nishat Hamza
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Genetic counseling ,Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Population ,Hematology ,Disease ,Alpha-thalassemia ,medicine.disease ,Molecular analysis ,Cohort ,medicine ,Intermedia ,business ,education ,Genetics (clinical) - Abstract
Sickle cell disease is known to be very common in the Omani population, although data are limited concerning β-thalassemia (β-thal). We report the molecular background of 87 unrelated patients from the Sultanate of Oman, diagnosed with β-thal major (β-TM), β-thal intermedia (β-TI) or minor. Diagnosis was based on clinical and hematological data and confirmed by molecular analysis. We found 11 different β-thal determinants in our cohort, which consists of subjects from different regions of Oman. Six of these mutations have not been previously reported in the Omani population. The prevalence of α-thal single gene deletions (−α3.7 and −α4.2) in the same cohort was very high (58.3%). These data will contribute to the implementation of a country-wide service for early molecular detection of hemoglobinopathies and for providing genetic counseling following premarital screening.
- Published
- 2010
33. A brief review on newborn screening methods for hemoglobinopathies and preliminary results selecting beta thalassemia carriers at birth by quantitative estimation of the HbA fraction
- Author
-
Jaqueline M. Beckhoven van, Sandra G.J. Arkesteijn, Cornelis L. Harteveld, Eleni Mantikou, Jean-Louis Kerkhoffs, and Piero C. Giordano
- Subjects
Heterozygote ,Pediatrics ,medicine.medical_specialty ,Thalassemia ,Clinical Biochemistry ,Gestational Age ,beta-Globins ,Cohort Studies ,Neonatal Screening ,Pregnancy ,Ethnicity ,Prevalence ,medicine ,Humans ,Fraction (mathematics) ,Newborn screening ,business.industry ,beta-Thalassemia ,Infant, Newborn ,Beta thalassemia ,Gestational age ,Hemoglobin A ,Sequence Analysis, DNA ,General Medicine ,medicine.disease ,Hemoglobinopathies ,Beta-thalassaemia ,Dutch Population ,Female ,business ,Cohort study - Abstract
We present in a brief summary the basic aspects of the most rational technologies used for new born screening (NBS) of the hemoglobinopathies and we report the preliminary results for the identification of beta-thalassemia carriers at birth by measuring the expression of the HbA fraction.Separation and measurement of the Hb fractions in 1.500 cord blood samples collected among the multi-ethnic Dutch population using different methods.By using a cut of15% HbA we have found 4 carriers of point mutations defects 3 of which among a group of 34 newborns of ethnic origin and one among 120 north Europeans.All methods for NBS summarized in this paper provide identification at practically 100% sensitivity and high specificity. However, all methods should be followed by routine parent's analysis to confirm the provisional results. Taking into consideration the gestation age and the HbA expression, we believe that carriers of beta-thalassemia can be preselected at birth with a reasonable degree of sensitivity and be confirmed by parent analysis.
- Published
- 2009
34. Hb Nile[A1] and Hb Nile[A2]: Novel Identical [α77(EF6)Pro→Ser] Variants Found in Either the α1- or α2-Globin Genes
- Author
-
Cornelis L. Harteveld, Jan Kouwenberg, Piero C. Giordano, Judith O. Kaufmann, Arthur J. Verhoeven, Kea Fogelberg, Rob van Zwieten, and Herma Vuil
- Subjects
Mutation ,Isoelectric focusing ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,Biology ,medicine.disease_cause ,medicine.disease ,Molecular biology ,Hemoglobinopathy ,Mutant protein ,medicine ,Hemoglobin ,Globin ,Alpha globulin ,Gene ,Genetics (clinical) - Abstract
We describe a novel hemoglobin (Hb) variant, caused by a CCC > TCC transition at codon 77 on the alpha gene. The mutation was found in two unrelated patients, in one patient on the alpha1 gene and in the other patient on the alpha2 gene. Both are anemic patients of African origin. Due to the neutral Pro-->Ser substitution, Hb Nile could not be separated from Hb A with common short-run screening methods for high performance liquid chromatography (HPLC) and capillary electrophoresis, but was evidently present after prolonged cation exchange HPLC or separation by isoelectric focusing (IEF). Reversed phase HPLC separation of the globin chains revealed the normal and abnormal alpha chains with an expression of about 20% for Hb Nile[A1], indicative of normal expression and stability of the mutant protein.
- Published
- 2009
35. Homozygosity for a Rare β0-Thalassemia Mutation [Frameshift Codons 25/26 (+T)] Causes β-Thalassemia Intermedia in an Iranian Family
- Author
-
Nasser Pouladi, Mohammad A. Hosseinpour Feizi, Mehdi Haghi, Abbas Ali Hosseinpour Feizi, and Cornelis L. Harteveld
- Subjects
Thalassemia ,Clinical Biochemistry ,beta-Globins ,Iran ,Biology ,Polymorphism, Single Nucleotide ,Frameshift mutation ,Polymorphism (computer science) ,medicine ,Humans ,Blood Transfusion ,gamma-Globins ,Frameshift Mutation ,Promoter Regions, Genetic ,Gene ,Genetics (clinical) ,Family Health ,Genetics ,Homozygote ,beta-Thalassemia ,Biochemistry (medical) ,Hematology ,medicine.disease ,Phenotype ,Pedigree ,Mutation (genetic algorithm) ,Hemoglobin ,Intermedia - Abstract
The severity of beta-thalassemia (beta-thal) is remarkable for its variability in different populations, even in different patients. We studied a family from Azerbaijan Province, Northwestern Iran, who had a rare beta(0)-thal mutation, namely the frameshift codons (FSC) 25/26 (+T), originally reported in Tunisia. Unlike the Tunisian family, in our family the mutation was a beta(0) type and the affected members were dependent and independent of blood transfusions. This mutation was linked to the -158 (CT) polymorphism on the (G)gamma-globin gene (XmnI marker) and two other polymorphisms in the (A)gamma-globin promoter at position +25 (GA) and -588 (GA). Deletions in the alpha- and beta-globin gene clusters were excluded in all samples. This is the first description of the FSC 25/26 mutation in Iran. The results of this study emphasize the complexity of genetic interactions that underlie the phenotype of beta-thal intermedia and highlight the importance of the regulation of hemoglobin (Hb) F production in the beta-thal syndromes. Simultaneous inheritance of some loci that interfere with the elevation of Hb F probably caused them to have high levels of total Hb and to be transfusion independent.
- Published
- 2009
36. Frequency of α-Globin Gene Triplications and Their Interaction with β-Thalassemia Mutations
- Author
-
Margaretha Bakker-Verwij, Piero C. Giordano, and Cornelis L. Harteveld
- Subjects
Male ,Genetics ,Hematologic Tests ,Thalassemia ,beta-Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Gene Amplification ,Hematology ,Biology ,medicine.disease ,Phenotype ,Molecular biology ,Multiethnic population ,Cohort Studies ,alpha-Globins ,medicine ,Humans ,Female ,Diagnostic laboratory ,α globin gene ,Gene ,Genetics (clinical) - Abstract
Our protocol for specialized diagnostics includes routine alpha-globin gene analysis for all blood samples referred to our diagnostic laboratory. alpha-Globin gene triplication is found to be present in more than 1% of samples tested. Since all cases with single alpha-gene triplications are associated with normal hematological parameters, we assume that preselection does not bias our observation and that alpha-globin gene triplications should be expected at the same frequency in the unselected Dutch multiethnic population as well. We have compared the average hematological parameters of beta-thalassemia (beta-thal) carriers with those of carriers with an associated alpha-gene triplication. In all cases, a single additional alpha gene had a very limited effect on the beta-thal minor phenotypes.
- Published
- 2009
37. Unstable and Thalassemic α Chain Hemoglobin Variants: A Cause of Hb H Disease and Thalassemia Intermedia
- Author
-
Piero C. Giordano, Ioannis Papassotiriou, Cornelis L. Harteveld, Véronique Baudin-Creuza, Henri Wajcman, J. Traeger-Synodinos, and John Old
- Subjects
Genetics ,Anemia ,Hemoglobins, Abnormal ,Point mutation ,Biochemistry (medical) ,Clinical Biochemistry ,Genetic Variation ,Hemoglobin variants ,Alpha (ethology) ,Hematology ,Biology ,medicine.disease ,Phenotype ,Molecular biology ,Hemolysis ,Globins ,alpha-Thalassemia ,Genotype ,medicine ,Chemical Precipitation ,Humans ,Genetics (clinical) ,Alpha chain ,Protein Binding - Abstract
We report an update of the alpha-globin gene point mutations resulting in structural modification associated with an alpha-thalassemia (alpha-thal) phenotype. These variants, barely symptomatic in the heterozygous state, are either unstable due to folding defects and/or defects in binding to alpha-hemoglobin stabilizing protein (AHSP). This is predicted to result in precipitation of the unstable alpha chains or Hb variant, a concomitant decrease in the overall quantity of normal alpha-globin in the red cells and a potential degree of anemia and possibly, hemolysis. Genotype/phenotype correlation and potential genetic risk in combination with common or less common alpha-thal defects are discussed.
- Published
- 2008
38. Hb Lepore-Leiden: A New δ/β Rearrangement Associated with a β-Thalassemia Minor Phenotype
- Author
-
Pierre W. Wijermans, Cornelis L. Harteveld, Piero C. Giordano, Sandra G.J. Arkesteijn, Jean-Louis H. Kerkhoffs, and Peter van Delft
- Subjects
Genetics ,Hemolytic anemia ,Biochemistry (medical) ,Clinical Biochemistry ,Hepatosplenomegaly ,Prenatal diagnosis ,Hematology ,Biology ,Compound heterozygosity ,medicine.disease ,Phenotype ,Hemoglobinopathy ,medicine ,medicine.symptom ,Beta (finance) ,Gene ,Genetics (clinical) - Abstract
The Lepore hemoglobins (Hbs) are a group of structural defects resulting from different recombination events between the delta- and beta-globin genes. They may come with different beta-thalassemia (beta-thal) minor-like phenotypes in the carrier and with variably severe phenotypes in the rare homozygote, and in the common compound heterozygote with beta-thal. The most seriously affected patients are those of Yugoslavian origin presenting with severe transfusion-dependent hemolytic anemia, dyserythropoiesis, hepatosplenomegaly and skeletal malformations. Because of genetic risk, couples where both partners are carriers of these combinations may require prognosis and prenatal diagnosis. In these cases, recognition of the defect must be done with particular care. We report a case of Hb Lepore induced by a yet unknown crossover event found in a 24-year-old Turkish male and compare the novel mutation with those previously reported.
- Published
- 2008
39. The Rare Hb Showa-Yakushiji [β110(G12)Leu→Pro, CTG→CCG] in Combination with an α Gene Triplication Found in a Dutch Patient During Her First Pregnancy Examination
- Author
-
Cornelis L. Harteveld, Peter van Delft, Piero C. Giordano, Akosua Addo-Daaku, Margaretha J. Sander, Irene H. Van Rooijen‐Nijdam, and Peter J.M.J. Kok
- Subjects
Adult ,Proline ,Hemoglobins, Abnormal ,Clinical Biochemistry ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,Loss of heterozygosity ,Gene product ,Leucine ,Pregnancy ,medicine ,Humans ,Amino Acid Sequence ,Gene ,Genetics (clinical) ,Genetics ,Mutation ,Base Sequence ,Transition (genetics) ,business.industry ,Biochemistry (medical) ,DNA ,Hematology ,medicine.disease ,Molecular biology ,Phenotype ,Hemoglobinopathy ,Amino Acid Substitution ,Gestation ,Female ,business - Abstract
We report a semi dominant beta-thalassemia (thal) phenotype caused by the rare Hb Showa-Yakushiji [beta110(G12)Leu-->Pro, CTG-->CCG] mutation in combination with an alpha gene triplication. This combination of two rare mutations was observed during hemoglobinopathy carrier diagnostics in a 26-year-old Dutch female at 9 weeks gestation, at the first pregnancy examination in the midwives practice. The partner was promptly examined and no abnormalities were found. The beta-thal trait was diagnosed by a standard high performance liquid chromatography (HPLC) procedure showing a normal separation but an elevated Hb A(2) level of 5.9% in the presence of pronounced hypochromic microcytic parameters and mild chronic hemolysis. Direct sequencing of the beta-globin genes was subsequently performed revealing a CTG-->CCG transition at codon 110. This rare mutation was previously described as two independent events in a few Japanese and Indian individuals. The mutation induces a Leu-->Pro substitution and the gene product is highly unstable. Gap-polymerase chain reaction (gap-PCR) revealed a heterozygosity for the alpha gene triplication as well. The excess of alpha-globin chains contributed only marginally to the hematological abnormalities of the patient and did not aggravate the phenotype to an intermediate level.
- Published
- 2007
40. Hb Zoetermeer: A New Mutation on the α2 Gene Inducing an Ala→Ser Substitution at Codon 21 is Possibly Associated with a Mild Thalassemic Phenotype
- Author
-
Henri Wajcman, Willem C. H. Van Helden, Cornelis L. Harteveld, Peter van Delft, Michel Becchi, Isabelle Zanella-Cléon, Piero C. Giordano, Margaretha Bakker-Verweij, and George L. Boxma
- Subjects
Male ,Protein Conformation ,Hemoglobins, Abnormal ,Thalassemia ,Clinical Biochemistry ,Biology ,Polymerase Chain Reaction ,medicine ,Humans ,Missense mutation ,Transversion ,Gene ,Genetics (clinical) ,Genetics ,Biochemistry (medical) ,Breakpoint ,Hematology ,Middle Aged ,medicine.disease ,Molecular biology ,Globins ,Phenotype ,Hemoglobinopathy ,Amino Acid Substitution ,Mutation ,Mutation (genetic algorithm) ,Neutral mutation - Abstract
A 52-year-old Dutch male was referred to our laboratory for hemoglobinopathy analysis because of persistent microcytic hypochromic parameters and moderate erythrocytosis in the absence of iron deficiency. The hemoglobin (Hb) pattern was normal and breakpoint polymerase chain reaction (PCR) excluded the six common deletion defects of the alpha gene cluster. Direct sequencing revealed a GCT-->TCT transversion at codon 21 of the alpha2 gene generating an Ala-->Ser single amino acid substitution. The hematological parameters observed in the presence of this mutation are consistent with a compensated heterozygous alpha(+)-thalassemia (thal). However, the neutral mutation and the external position of the residue do not explain an association with this phenotype. Nevertheless, we cannot exclude that the mutation could induce the observed hematological abnormalities and could eventually be considered as a mutation associated with a mild alpha-thalassemic phenotype.
- Published
- 2007
41. A Novel Targeted Approach for Noninvasive Detection of Paternally Inherited Mutations in Maternal Plasma
- Author
-
Ivonne J. H. M. van Minderhout, Nicolette S. den Hollander, Egbert Bakker, Jessica M.E. van den Oever, Elles M. J. Boon, Nienke van der Stoep, Cornelis L. Harteveld, and Human genetics
- Subjects
Male ,DNA Mutational Analysis ,Inheritance Patterns ,Mothers ,Prenatal diagnosis ,Biology ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,Melting curve analysis ,Pathology and Forensic Medicine ,Fathers ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Mutation detection ,Allele ,Germ-Line Mutation ,Genetics ,Fetus ,Mutation ,Plasma dna ,Genetic Diseases, Inborn ,DNA ,medicine.disease ,Pedigree ,Molecular Medicine ,Female ,Trisomy ,Blood Chemical Analysis - Abstract
The challenge in noninvasive prenatal diagnosis for monogenic disorders lies in the detection of low levels of fetal variants in the excess of maternal cell-free plasma DNA. Next-generation sequencing, which is the main method used for noninvasive prenatal testing and diagnosis, can overcome this challenge. However, this method may not be accessible to all genetic laboratories. Moreover, shotgun next-generation sequencing as, for instance, currently applied for noninvasive fetal trisomy screening may not be suitable for the detection of inherited mutations. We have developed a sensitive, mutation-specific, and fast alternative for next-generation sequencing-mediated noninvasive prenatal diagnosis using a PCR-based method. For this proof-of-principle study, noninvasive fetal paternally inherited mutation detection was performed using cell-free DNA from maternal plasma. Preferential amplification of the paternally inherited allele was accomplished through a personalized approach using a blocking probe against maternal sequences in a high-resolution melting curve analysis-based assay. Enhanced detection of the fetal paternally inherited mutation was obtained for both an autosomal dominant and a recessive monogenic disorder by blocking the amplification of maternal sequences in maternal plasma.
- Published
- 2015
42. Hb Bleuland [α108(G15)Thr→Asn, ACC→AAC (α2)]: A New Abnormal Hemoglobin Associated with a Mild α-Thalassemia Phenotype
- Author
-
Florens G. A. Versteegh, Cornelis L. Harteveld, Peter van Delft, Irene H. Van Rooijen‐Nijdam, Piero C. Giordano, and Peter J.M.J. Kok
- Subjects
Genetics ,Proband ,Mutation ,Chemistry ,Sequence analysis ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,Alpha-thalassemia ,medicine.disease_cause ,medicine.disease ,Abnormal hemoglobin ,medicine ,Asparagine ,Threonine ,Transversion ,Genetics (clinical) - Abstract
We report a new structural defect of the alpha2-globin chain, not detectable on high performance liquid chromatography (HPLC) or electrophoresis, characterized in a 12-year-old boy of Surinamese-Hindustani origin. The child was suspected to be a carrier of alpha-thalassemia (thal) because of microcytic hypochromic parameters in the absence of iron depletion. Gap-polymerase chain reaction (gap-PCR) revealed only normal fragments in the proband, and the pattern of a -alpha4.2 (leftward) deletion in his father and sister. Direct sequencing of the alpha-globin genes revealed an ACC-->AAC transversion at codon 108 of the alpha2-globin gene in the proband, in his mother and in a younger sister. The new mutation predicts a Thr -->Asn amino acid substitution at the corresponding residue. Threonine, a covalent binder with an R-active OH group, situated in the G helix of the alpha-globin chain, is involved in alpha1beta1 contacts. Asparagine, being an equally covalent binder but with a different R-active H2N-C=O group, could make the mutated chain less suitable for tetramer cooperation. Alternatively, an absent or reduced interaction with the alpha hemoglobin (Hb) stabilizing protein (AHSP) could lead to loss of alpha chains. Hb Bleuland is the first mutation described at codon 108 and is therefore interesting in regard to the possible effects and genetic risk. The nearest variant, Hb Suan-Dok [alpha109(G16)Leu -->Arg, CTG-->CGG (alpha2)] was originally observed in a Thai patient affected with Hb H, in combination with an alpha0-thal allele. The same Hb Suan-Dok mutation, recently described in our laboratory in a carrier of African ancestry, was also not detectable as a protein and presented with an alpha-thal phenotype similar to Hb Bleuland.
- Published
- 2006
43. Known and New delta-Globin Gene Mutations and Other Factors Influencing Hb A(2) Measurement in the Omani Population
- Author
-
Suha M. Hassan, Cornelis L. Harteveld, Piero C. Giordano, and Egbert Bakker
- Subjects
Male ,Genotype ,Oman ,Genetic counseling ,Thalassemia ,HBD ,Clinical Biochemistry ,Population ,DNA Mutational Analysis ,Severe disease ,Biology ,Gene mutation ,hemic and lymphatic diseases ,medicine ,Humans ,Globin gene ,Hemoglobin A2 ,education ,Codon ,Gene ,Genetics (clinical) ,Chromatography, High Pressure Liquid ,beta-Thalassemia (beta-thal) ,Genetics ,education.field_of_study ,delta-Globins ,Biochemistry (medical) ,Hematology ,medicine.disease ,delta-Thalassemia ,Hb A(2) ,Mutation ,Female ,delta-globin gene mutation - Abstract
Although δ-thalassemia (δ-thal) is not categorized as a severe disease, it is essential to know the molecular spectrum of the δ gene mutations frequently occurring in specific areas, particularly if these areas are characterized by a high rate of β-thalassemia (β-thal) such as Oman. This is because coinherited δ-globin gene defects can interfere with the basic diagnosis of a β-thal carrier when this is based upon the measurement of the Hb A2 only. Because of that, we have investigated 33 patients with low Hb A2 levels, collected from different hospitals in Oman. Some cases had a second Hb A2 fraction, while others had only significantly lower Hb A2 levels. Among these patients, 20 did carry a δ-globin gene mutation, the rest were carriers of α thalassemia (α-thal) defects or could be iron depleted or both. In total, eight different known mutations and two novel δ variants were found. The characterization of the δ-globin gene mutation spectrum will improve carrier diagnostics and genetic counseling in the Omani population screened for β-thal.
- Published
- 2014
44. Hb Amsterdam [α32(B13)met→ile (α2)]
- Author
-
Peter van Delft, Sandra Arkestijn, Sonja Zweegman, Nicole Akkermans, Piero C. Giordano, Mark Vervloet, Cornelis L. Harteveld, Nephrology, and Hematology
- Subjects
Proband ,Adult ,medicine.medical_specialty ,Anemia ,Thalassemia ,Hemoglobins, Abnormal ,Clinical Biochemistry ,Black People ,alpha-Thalassemia ,Polymorphism (computer science) ,Internal medicine ,medicine ,Humans ,Point Mutation ,Renal Insufficiency ,Genetics (clinical) ,Sequence Deletion ,Genetics ,Family Health ,Anemia, Hypochromic ,Polymorphism, Genetic ,biology ,business.industry ,Point mutation ,Biochemistry (medical) ,Haptoglobin ,Genetic Variation ,Hematology ,medicine.disease ,Abnormal hemoglobin ,Endocrinology ,Hemoglobinopathy ,Phenotype ,Africa ,biology.protein ,Female ,business - Abstract
We have characterized a new abnormal hemoglobin (Hb) at position 32 of the alpha-globin chain. The proband, a 38-year-old woman of Surinamese Black ancestry, was referred to the Academic Hospital in Amsterdam, The Netherlands, after 3 years of Prednisone treatment in Surinam. Kidney failure was diagnosed at the Nephrology Department, Free University Medical Center, Amsterdam, The Netherlands; the cortisone treatment was interrupted and dialysis was started. At this stage, a microcytic hypochromic anemia was observed with high reticulocyte (40%) and ferritin (500 microg/L) levels, and hemoglobinopathy was suspected. No abnormal bands were visible on alkaline electrophoresis and high performance liquid chromatography (HPLC). The Hb A2 level was normal (2.7%) and the erythrocyte count was low (3.59 x 10(12)/L) with a normal haptoglobin level (68 mg/100 mL). None of the common alpha-thalassemia (thal) deletion defects were present. The beta-globin gene sequence was normal but the alpha2-globin gene sequence revealed an ATG-->ATA transition at codon 32, changing the methionine into an isoleucine residue. The mutation, called Hb Amsterdam, was observed in the mother of the proband, who was also heterozygous for the--alpha3.7-thal deletion and affected by a moderate microcytic hypochromic anemia. Both Hb Amsterdam and the--alpha(-3.7) allele were found in association with a new polymorphism, IVS-I-39 (C-->T), previously observed in our laboratory in seven patients of African origin, on both the alpha1 and alpha2 genes. In addition, Hb Amsterdam was also associated with the common African alpha2 polymorphism (G-->CTCGGCCC at position 7238 and T-->G at position 7174). Hb Amsterdam is the first mutation ever described at codon alpha32, a position involved in alpha1/beta1 interaction. The possibility of a contribution of this mutation to the nephropatic state of the proband is discussed.
- Published
- 2005
45. Hb Geldrop St. Anna [β94(FG1)Asp→Tyr]: a New Hemoglobin Variant Observed in a Diabetic Patient
- Author
-
Nicole Akkermans, Jolanda Leuverman, Peter van Delft, Piero C. Giordano, Marc H. M. Thelen, Sandra G.J. Arkesteijn, Cornelis L. Harteveld, and Johannes J. A. Rutten
- Subjects
Chromatography ,P50 ,Anemia ,Biochemistry (medical) ,Clinical Biochemistry ,Hemoglobin variants ,Hematology ,Biology ,medicine.disease ,Molecular biology ,High-performance liquid chromatography ,Abnormal hemoglobin ,Red blood cell ,medicine.anatomical_structure ,Diabetes mellitus ,medicine ,Transversion ,Genetics (clinical) - Abstract
An abnormal hemoglobin (Hb) fraction was observed during a high performance liquid chromatographic (HPLC) Hb A1c control for diabetes mellitus in a 56-year-old north European woman. Family analyses revealed the abnormal fraction in three of her five siblings and in her son. Elevated Hb and packed cell volume (PCV) values and red blood cell (RBC) counts were present in all carriers. No histories of anemia, hemolytic or circulatory episodes were reported. The abnormal Hb fraction estimated at 40%, migrated just below Hb F on alkaline electrophoresis and overlapped the Hb A2 peak on cation exchange HPLC. Direct sequencing of the beta-globin genes revealed a new GAC --> TAC transversion in heterozygous form at codon 94 of the beta-globin gene. Based on the hematological/biochemical data and the decreased P50 value, we conclude that the new variant is a stable Hb associated with a slightly elevated oxygen affinity.
- Published
- 2005
46. Molecular Basis of Hb H Disease in Southwest Iran
- Author
-
Piero C. Giordano, Mehran Karimi, Amine Zorai, Majid Yavarian, Cornelis L. Harteveld, Hemoglobinopathies Laboratory, Department of Human and Clinical Genetics, Leiden University Medical Center (LUMC), Hematology Research Centre, School of Medicine, Shiraz University of Medical Sciences [Iran] (SUMS), Laboratoire d'hématologie moléculaire et cellulaire (LR11IPT07), Institut Pasteur de Tunis, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,Hemoglobins, Abnormal ,Thalassemia ,education ,Clinical Biochemistry ,Alpha (ethology) ,Iran ,Biology ,Southeast asian ,Polymerase Chain Reaction ,law.invention ,Cohort Studies ,law ,Hydrops fetalis ,Genotype ,medicine ,Humans ,Hb h disease ,Genetic Testing ,Genetics (clinical) ,Polymerase chain reaction ,Hemoglobin H ,Incidence (epidemiology) ,Biochemistry (medical) ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Anemia ,Hematology ,medicine.disease ,Molecular biology ,Hb H disease ,Mutation ,Female ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,geographic locations - Abstract
International audience; Although alpha(0)-thalassemia (thal) defects are not very frequent in the Iranian population, Hb H disease does occur in the country. We have analyzed the alpha gene cluster of 13 patients showing the presence of Hb H to establish the molecular background of this disease in southwest Iran (Shiraz and Hormozgan provinces). Using gap-polymerase chain reaction (gap-PCR) and direct DNA sequencing we have found the ―(MED-I) deletion, the polyadenylation signal (poly A) mutations alpha(T-Saudi)alpha and alpha(T-Turkish)alpha, and Hb Constant Spring (Hb CS) in association with the common -alpha(3.7) deletion. This study has revealed that: 1) at least six genotypes are responsible for Hb H disease in the area: -alpha(3.7)/ ―(MED-I); -alpha(3.7)/alpha(T-Saudi)alpha; alpha(T-Saudi)alpha/alpha(T-Saudi)alpha; alpha(CS)alpha/―(MED-I); ―(MED-I)/alpha(T-Turkish)alpha; and the atypical forms of Hb H disease -alpha(3.7)/alpha(CS)alpha. 2) The molecular background of Hb H disease in the southwest area of Iran is more similar to the Mediterranean type than to the Southeast Asian. 3) Hb Bart's hydrops fetalis syndrome and mild, intermediate or severe postnatal Hb H disease conditions can be expected, but at a relatively low incidence. 4) The diagnostic flowchart for patients with microcytic hypochromic anemia should include iron deficiency, beta-thal, alpha(+)- and alpha(0)-thal analyses.
- Published
- 2005
47. Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in β-thalassemia major and the first E277K homozygous
- Author
-
Shirin Farjadian, Cornelis L. Harteveld, Paola Delbini, Mehran Karimi, Piero C. Giordano, Majid Yavarian, and Gemino Fiorelli
- Subjects
Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Hemoglobins, Abnormal ,Thalassemia ,DNA Mutational Analysis ,Iran ,Biology ,Chromosomes ,Gene Frequency ,medicine ,Humans ,Child ,Hemochromatosis Protein ,Base Pairing ,Allele frequency ,Hemochromatosis ,Genetics ,Polymorphism, Genetic ,Transition (genetics) ,Histocompatibility Antigens Class I ,Homozygote ,beta-Thalassemia ,Haplotype ,Infant, Newborn ,Membrane Proteins ,Beta thalassemia ,Hematology ,medicine.disease ,humanities ,Genetics, Population ,Haplotypes ,Ferritins ,Mutation (genetic algorithm) ,Mutagenesis, Site-Directed ,Mutation testing - Abstract
We present the molecular analysis of HFE gene in 400 Southwest Iranian individuals. We have studied 43 newborn, selected for the presence of HbBart's at birth, 203 normal adult and 154 transfused patients affected with beta-thalassemia. Mutation analysis consisted of amplification and direct sequencing using two different pairs of forward and reverse primers. The C282Y and S65C mutations were not found. The H63D mutation was present with an allele frequency of 0.10 in newborns, 0.082 in normal adults and 0.080 in the beta-thalassemia major populations, respectively. No differences were found between normal adults and thalassemia major patients suggesting that this mutation does not increase mortality in beta-thalassemia. The H63D mutation was found associated with haplotype VI in 41% of the chromosomes. Other haplotypes were found suggesting a multicentric origin rather than a single mutation of European origin. While sequencing exon 4, a G --> A transition was found in the proximity of the C282Y mutation. The effect of this single base substitution (E277K) previously reported in an Asian individual and now found in homozygous form in a young transfused and chelated homozygous beta-thalassemia patient is not yet known.
- Published
- 2004
48. A Confidential Inquiry Estimating the Number of Patients Affected with Sickle Cell Disease and Thalassemia Major Confirms the Need for a Prevention Strategy in The Netherlands
- Author
-
Cornelis L. Harteveld, Marelle J. Bouva, and Piero C. Giordano
- Subjects
Health Services Needs and Demand ,medicine.medical_specialty ,business.industry ,Thalassemia ,beta-Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Anemia, Sickle Cell ,macromolecular substances ,Hematology ,Disease ,Emigration and Immigration ,medicine.disease ,humanities ,Family medicine ,Humans ,Medicine ,Confidentiality ,business ,Genetics (clinical) ,Netherlands - Abstract
We have conducted a broad confidential inquiry among 401 hospital departments trying to estimate the number of patients affected with severe forms of hemoglobinopathies living in The Netherlands. With less than 30% response we have registered 559 patients in all age categories of whom 77.0% are affected with sickle cell disease and 17.5% with beta-thalassemia (thal) major. We estimate that the real figure could be around 800 patients, a figure more than six times higher than the number published in 1995 on which the reluctance to offer prevention was based. The actual figures and the incidence estimation of approximately 60 patients a year underline the urgent need for the official implementation of a prevention strategy in The Netherlands. During the last 5 years we have been working towards the implementation of a multi-intervention strategy for primary prevention using the existing structures of public health. The obstacles we have encountered to endorse such a strategy are discussed as a possible guide for other immigration countries.
- Published
- 2004
49. Hb Suan‐Dok [α109(G16)Leu→Arg; CTG→CGG (α2)] Described in a Patient of African Ancestry
- Author
-
Piero C. Giordano, Nicole Akkermans, Cornelis L. Harteveld, Marlies E. Regtuijt, and Peter van Delft
- Subjects
Genetics ,Mutation ,Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,Biology ,medicine.disease_cause ,medicine.disease ,Molecular biology ,High-performance liquid chromatography ,Abnormal hemoglobin ,Tetramer ,Hb Suan-Dok ,medicine ,Allele ,Gene ,Genetics (clinical) - Abstract
A 58‐year‐old Black female from Curacao (West Indies) was recently referred to our Laboratory for a persistent microcytic hypochromic anemia. An analysis 13 years earlier had shown no abnormal hemoglobin (Hb) fractions and a balanced β/α synthetic ratio. The hematological indices were again compatible with thalassemia and no abnormal fractions were observed on electrophoresis or high‐performance liquid chromatography (HPLC). None of the seven common α‐thalassemia (thal) deletion defects were present. Direct sequencing of the α2 gene revealed a CTG→CGG single base substitution at codon 109. This mutation was previously described in a Thai patient (Hb Suan‐Dok), inducing Hb H disease in association with a – –SEA allele. In contrast with earlier reports we were unable to identify any native Hb fraction. The balanced β/α ratio indicated that α2‐Suan‐Dok is formed but does not form tetramer formation unless α‐thal is present.
- Published
- 2004
50. Paediatric allogeneic bone marrow transplantation for homozygous β-thalassaemia, the Dutch experience
- Author
-
Piero C. Giordano, Robbert G. M. Bredius, Lynne M. Ball, M. Van Weel, Arjan C. Lankester, Cornelis L. Harteveld, R.M. Egeler, Jaak M. Vossen, and Frans J. Smiers
- Subjects
Graft Rejection ,Male ,Hemolytic anemia ,Melphalan ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,Cyclophosphamide ,Graft vs Host Disease ,Gastroenterology ,Disease-Free Survival ,Chimera (genetics) ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Child ,Bone Marrow Transplantation ,Netherlands ,Transplantation ,Chimera ,business.industry ,Graft Survival ,Homozygote ,beta-Thalassemia ,Infant ,Beta thalassemia ,Hematology ,medicine.disease ,Surgery ,surgical procedures, operative ,Hemoglobinopathy ,medicine.anatomical_structure ,Child, Preschool ,Female ,Bone marrow ,business ,medicine.drug - Abstract
We reviewed the results of the Dutch paediatric bone marrow transplant (BMT) program for children receiving HLA-identical BMT for beta-thalassaemia major over an 18-year period. In all, 19 patients underwent a total of 21 transplants in our treatment centre between July 1984 and February 2002. Eight females (age 0.3-12 years; median 5 years) and 11 males (age 0.8-18 years; median 6 years) were included. Information, prospectively collected, included molecular defects, donor genotype, beta/alpha-globin expression rates, serum ferritin levels, hepato-splenomegaly, chelation history, virology screening, liver pathology together with post-transplant outcome inclusive of leucocyte chimerism. In total, 11 patients received standard busulphan/cyclophosphamide (Bu/Cy) conditioning, with or without ATG. Stable engraftment was seen in 5/11 with late rejection occurring in six patients. Of these, two children underwent a second successful SCT. For this group, overall event-free survival (EFS) and disease-free survival (DFS) were 90 (10/11) and 64% (7/11), respectively. The probability of rejection was 55%. Subsequent addition of melphalan to the conditioning regimen resulted in long-term stable engraftment in all patients with an EFS/DFS for this group of 90% (9/10). Treatment-related mortality, irrespective of conditioning, was low at 5% (1/19 patients). Veno-occlusive disease (VOD) occurred in 19% (4/21 transplants) and acute GvHD in 19% (4/21 transplants). Post-BMT beta/alpha synthetic ratio measurement monitored donor erythroid engraftment and predicted rejection with a return to transfusion dependency. Maintained full donor chimerism is indicative of stable engraftment both for leucocyte and erythroid lineages, whereas mixed donor chimerism is not. Our results emphasise the importance of the conditioning regimen and post-transplant chimerism surveillance predictive of rejection or long-term stable engraftment.
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.